Physician profile
Dan Mario Udrea
NPI 1104072800
$51,080.94
in general payments reported to CMS, 2019-2025
18 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.42 · 2021: $508 · 2022: $468 · 2023: $5,272 · 2024: $1,128 · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $38K · Food and Beverage: $4,506 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,360 · Travel and Lodging: $3,234 · Consulting Fee: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $38,250.00 |
| Food and Beverage | $4,506.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,360.00 |
| Travel and Lodging | $3,233.82 |
| Consulting Fee | $720.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $43,340.56 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $4,912.10 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $617.58 | 2020-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $599.10 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $416.97 | 2021-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $400.36 | 2023-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $211.01 | 2025 | Jornay Pm |
| Abbvie INC. | $131.18 | 2023-2025 | Vraylar |
| Neos Therapeutics, Lp | $106.68 | 2021-2023 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.34 | 2025 | Caplyta |
| Vertical Pharmaceuticals, LLC | $74.81 | 2024-2025 | Relexxii |
| Otsuka America Pharmaceutical, INC. | $51.84 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Avion Pharmaceuticals | $32.13 | 2023 | Dhivy, Methylphenidate Hydrochloride |
| Neuronetics, INC. | $26.32 | 2024-2025 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $19.31 | 2025 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $16.19 | 2022 | |
| Lundbeck LLC | $14.40 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Udrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.